Malcolm Young awarded Ernst & Young Innovation Entrepreneur Of The Year 2010
News
Positive Phase IIa clinical trial of the Company's oral asthma treatment
Press Release 10 October 2008
e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce the successful conclusion of the Company’s Phase IIa clinical trial of ETX9101, a new oral treatment for asthma which has the potential to reduce exacerbation of asthma and to reduce the intake of inhaled corticosteroids and bronchodilators, thereby reducing their side-effects.
e-Therapeutics expands its global footprint in China through partnership with KeyGen Biotechnology
Press Release: 15 September 2008
ETS2101 effective in in vitro studies against skin cancer and commences in vivo studies
Press Release: 22 January 2008
Successful completion of preclinical efficacy and resistance studies of candidate antibiotic ETX1153 against MRSA
Press Release: 10 December 2007
e-Therapeutics plc Intention to Float on AIM
Press Release: 8 October 2007
e-Therapeutics, the systems biology drug discovery company, today announces its intention to proceed with a placing of its shares and to seek admission of its share capital to trading on AIM, the market owned and operated by the London Stock Exchange.
e-Therapeutics Highlights:
1. Large market opportunity
e-Science identifies new weapons in battle against hospital superbugs
Source: Research Councils UK - 24/02/07 - View Source Article
Techniques developed under the UK e-Science Programme led to the identification of the anti-MRSA drugs that received widespread publicity in the UK national media last month.
New Weapon for MRSA?
Source: Pharma Times - 18/01/2007 - View Source Article
Scientists in the UK claim they have found an effective weapon against the superbug methicillin-resistant Staphylococcus aureas, by using a computer programme designed to analyse the bacteria’s ‘weak spots’ and then matching potential compounds against them.
Spin Out Company Tests MRSA Drugs
Source: University of Newcastle Upon Tyne - 18/01/2007 - View Source Article
A University spin-out company has announced the discovery of three drugs that kill the 'super bug' MRSA - and is now planning the final stages of clinical trials.
e-Therapeutics, a Newcastle-based systems biology drug discovery company, was established by Professor Malcolm Young (pictured), of Newcastle University, who is currently seconded to the company as its Chief Executive Officer.